alpha (1,3) galactosyltransferase expressing allogeneic tumor cells
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT00073398)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- alpha (1,3) galactosyltransferase expressing allogeneic tumor cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00073398 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2003 | National Cancer Institute (NCI), NewLink Genetics Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2003 |
| NewLink Genetics Inc | For profit | 1 | 1 | 1 | 2003 |
2 organizations
Page 1 / 1